What is the half-life of Amycretin?
Amycretin has a reported half life of ~5-7 days (sub-q form), given subcutaneous (sub-q form) or oral (oral form). That is why it is typically dosed once weekly (sub-q) or once daily (oral). A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: ~5-7 days (sub-q form)
- Route: Subcutaneous (sub-q form) or oral (oral form)
- Typical schedule: Once weekly (sub-q) or once daily (oral)
- Cycle length: Trial protocols
References
- Amycretin (Novo Nordisk), early Phase 1/2 obesity readouts — Novo Nordisk pipeline, 2024-2025
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Dahl K et al., The Lancet, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist amycretin: a first-in-human, phase 1 trial — Gasiorek A et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Amycretin
Last updated 2026-06-06.